178 related articles for article (PubMed ID: 37209032)
1. Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody.
Seth A; Murray D; Buadi FK; Gertz MA; Yadav U; Kumar SK; Gonsalves WI
Eur J Haematol; 2023 Aug; 111(2):318-321. PubMed ID: 37209032
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
3. Anti CD38 monoclonal antibodies for multiple myeloma treatment.
Gozzetti A; Ciofini S; Simoncelli M; Santoni A; Pacelli P; Raspadori D; Bocchia M
Hum Vaccin Immunother; 2022 Nov; 18(5):2052658. PubMed ID: 35404740
[TBL] [Abstract][Full Text] [Related]
4. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Nijhof IS; Casneuf T; van Velzen J; van Kessel B; Axel AE; Syed K; Groen RW; van Duin M; Sonneveld P; Minnema MC; Zweegman S; Chiu C; Bloem AC; Mutis T; Lokhorst HM; Sasser AK; van de Donk NW
Blood; 2016 Aug; 128(7):959-70. PubMed ID: 27307294
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.
Pick M; Vainstein V; Goldschmidt N; Lavie D; Libster D; Gural A; Grisariu S; Avni B; Ben Yehuda D; Gatt ME
Eur J Haematol; 2018 May; 100(5):494-501. PubMed ID: 29453884
[TBL] [Abstract][Full Text] [Related]
6. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
[TBL] [Abstract][Full Text] [Related]
7. The CD38
Sarkar S; Chauhan SKS; Daly J; Natoni A; Fairfield H; Henderson R; Nolan E; Swan D; Hu J; Reagan MR; O'Dwyer M
Cancer Immunol Immunother; 2020 Mar; 69(3):421-434. PubMed ID: 31919623
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.
Syed YY
Drugs; 2019 Mar; 79(4):447-454. PubMed ID: 30830601
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab: A review of current indications and future directions.
Hill E; Morrison C; Kazandjian D
Semin Oncol; 2022 Feb; 49(1):48-59. PubMed ID: 35184871
[TBL] [Abstract][Full Text] [Related]
10. Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.
Oberle A; Brandt A; Alawi M; Langebrake C; Janjetovic S; Wolschke C; Schütze K; Bannas P; Kröger N; Koch-Nolte F; Bokemeyer C; Binder M
Haematologica; 2017 Sep; 102(9):e368-e370. PubMed ID: 28522580
[No Abstract] [Full Text] [Related]
11. Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody.
Regidor BS; Siddiqi D; Beatty BM; Goldwater MS; Jew S; Bujarski S; Swift R; Kim S; Berenson JR
Eur J Haematol; 2023 Feb; 110(2):222-223. PubMed ID: 36367357
[No Abstract] [Full Text] [Related]
12. Should all newly diagnosed MM patients receive CD38 antibody-based treatment?
Korst CLBM; van de Donk NWCJ
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):259-263. PubMed ID: 33275735
[TBL] [Abstract][Full Text] [Related]
13. CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.
Wang H; Koob T; Fromm JR; Gopal A; Carter D; Lieber A
Cancer Biol Ther; 2024 Dec; 25(1):2314322. PubMed ID: 38361357
[TBL] [Abstract][Full Text] [Related]
14. CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy.
Minarik J; Novak M; Flodr P; Balcarkova J; Mlynarcikova M; Krhovska P; Pika T; Pikalova Z; Bacovsky J; Scudla V
Eur J Haematol; 2017 Aug; 99(2):186-189. PubMed ID: 28470777
[TBL] [Abstract][Full Text] [Related]
15. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
[TBL] [Abstract][Full Text] [Related]
18. Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma.
Lonial S; Bowser AD; Chari A; Costello C; Krishnan A; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):815-824. PubMed ID: 37516547
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
Sanchez L; Wang Y; Siegel DS; Wang ML
J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]